THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES
- 1 March 1983
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 321 (8324) , 551-555
- https://doi.org/10.1016/s0140-6736(83)92810-6
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- IMPROVEMENT OF CELLULAR IMMUNITY AND IgA PRODUCTION IN IMMUNODEFICIENT CHILDREN AFTER TREATMENT WITH SYNTHETIC SERUM THYMIC FACTOR (FTS)The Lancet, 1982
- Abnormalities of regulatory T-cell subpopulations in patients with primary immunoglobulin deficienciesClinical Immunology and Immunopathology, 1982
- Natural killer activity and lymphocyte subpopulations in patients with primary humoral and cellular immunodeficienciesClinical Immunology and Immunopathology, 1981
- RESPONSE TO TRYMOPOIETIN PENTAPEPTIDE IN PATIENT WITH DIGEORGE SYNDROMEThe Lancet, 1980
- Immunokinetics of a Single Dose of Thymopoietin PentapeptideJournal of Immunopharmacology, 1980
- In vitro and in vivo responses to thymosin in severe combined immunodeficiencyClinical Immunology and Immunopathology, 1979
- A Synthetic Pentapeptide with Biological Activity Characteristic of the Thymic Hormone ThymopoietinScience, 1979
- RECONSTITUTION OF B AND T LYMPHOCYTE FUNCTION IN SEVERE COMBINED IMMUNODEFICIENCY DISEASE AFTER TRANSPLANTATION WITH THYMIC EPITHELIUMThe Lancet, 1976
- Identification, Enumeration, and Isolation of B and T Lymphocytes from Human Peripheral BloodScandinavian Journal of Immunology, 1974
- Isolation of Bovine Thymin: a Polypeptide Hormone of the ThymusNature, 1974